Pazopanib and ARQ 197 for Advanced Solid Tumors

clinical trial

MedicalStudy clinical_trial Q61955908

Press Enter · cited answer in seconds

Summary

Pazopanib and ARQ 197 for Advanced Solid Tumors is a clinical trial^[1].

Key Facts

Pazopanib and ARQ 197 for Advanced Solid Tumors is in the country of United States^[2].
Pazopanib and ARQ 197 for Advanced Solid Tumors's instance of is recorded as clinical trial^[3].
Pazopanib and ARQ 197 for Advanced Solid Tumors's start time is recorded as +2011-10-25T00:00:00Z^[4].
Pazopanib and ARQ 197 for Advanced Solid Tumors's end time is recorded as +2014-09-30T00:00:00Z^[5].
Pazopanib and ARQ 197 for Advanced Solid Tumors's sponsor is recorded as National Cancer Institute^[6].
Pazopanib and ARQ 197 for Advanced Solid Tumors's main subject is recorded as cancer^[7].
Pazopanib and ARQ 197 for Advanced Solid Tumors's main subject is recorded as sarcoma^[8].
Pazopanib and ARQ 197 for Advanced Solid Tumors's number of participants is recorded as {'unit': '1', 'amount': '+32'}^[9].
Pazopanib and ARQ 197 for Advanced Solid Tumors's title is recorded as Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors^[10].
Pazopanib and ARQ 197 for Advanced Solid Tumors's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
Pazopanib and ARQ 197 for Advanced Solid Tumors's ClinicalTrials.gov ID is recorded as NCT01468922^[12].
Pazopanib and ARQ 197 for Advanced Solid Tumors's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+120'}^[13].
Pazopanib and ARQ 197 for Advanced Solid Tumors's clinical trial phase is recorded as phase I clinical trial^[14].
Pazopanib and ARQ 197 for Advanced Solid Tumors's research site is recorded as United States National Institutes of Health^[15].
Pazopanib and ARQ 197 for Advanced Solid Tumors's research subject recruitment status is recorded as completed^[16].
Pazopanib and ARQ 197 for Advanced Solid Tumors's study type is recorded as interventional study^[17].

⭐ Popularity Graph

0/100 long tail

⛏️ Lake Facts · open-dataset statements via 4ort-mint

From open datasets, joined by identifier and shown only for properties Wikidata does not state on this entity — except where the dataset is the registry authority for the fact (ClinicalTrials.gov on trial registration data): there its value is shown instead, with Wikidata's noted beside it. Every row carries its dataset edition and licence.

Start timeP580

2012-01-23 2026-09-26 Wikidata lists 2011-10-25 ClinicalTrials.gov (US Government Public Domain)

End timeP582

2016-02-11 2026-09-26 Wikidata lists 2014-09-30 ClinicalTrials.gov (US Government Public Domain)

ClinicalTrials.gov (data processed by ClinicalTrials.gov on 2026-09-26); U.S. federal government data, public domain; lake licence_code custom-review

Quick Facts

Instance of clinical trial

Country United States

Properties

Clinical trial phase phase I clinical trial

End time September 30, 2014

Imported from wholeness_audit_2026-05-02

Main subject cancer, sarcoma

Maximum age 120 year

Minimum age 18 year

Number of participants 32

Research site United States National Institutes of Health

Research subject recruitment status completed

Sponsor National Cancer Institute

Start time October 25, 2011

Study type interventional study

Title Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors

External References (1)

Clinicaltrials.gov id NCT01468922

🏷️ Also known as

en Pazopanib and ARQ 197 for Advanced Solid Tumors

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

Class ancestry

[1] ↑ Pazopanib and ARQ 197 for Advanced Solid Tumors is an instance of clinical trial (Q30612) [P31, primary]. Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA

4ort.xyz Knowledge Graph. (2026). Pazopanib and ARQ 197 for Advanced Solid Tumors. Retrieved May 3, 2026, from https://4ort.xyz/entity/pazopanib-and-arq-197-for-advanced-solid-tumors

MLA

“Pazopanib and ARQ 197 for Advanced Solid Tumors.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/pazopanib-and-arq-197-for-advanced-solid-tumors.

BibTeX

@misc{4ortxyz_pazopanib-and-arq-197-for-advanced-solid-tumors_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Pazopanib and ARQ 197 for Advanced Solid Tumors}}, year = {2026}, url = {https://4ort.xyz/entity/pazopanib-and-arq-197-for-advanced-solid-tumors}, note = {Accessed: 2026-05-03}}

LLM prompt

According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Pazopanib and ARQ 197 for Advanced Solid Tumors — https://4ort.xyz/entity/pazopanib-and-arq-197-for-advanced-solid-tumors (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/pazopanib-and-arq-197-for-advanced-solid-tumors · Last refreshed: May 3, 2026